Feed icon


chromosome 22q deletion

Parkinson's chromosome deletion linked to other genetic disorders

Researchers, led by BRC-supported Professor Nicholas Wood, UCL Institute of Neurology, have made a breakthrough in their understanding of Parkinson’s disease after they discovered a chromosome deletion linked to Parkinson’s disease and other genetic disorders. More...

Prof John Hardy

Prof John Hardy is the first UK winner of $3m Breakthrough Prize in Life Sciences

Professor John Hardy (UCL Institute of Neurology) has been awarded the $3 million Breakthrough Prize in Life Sciences for his pioneering research into the genetic causes of Alzheimer’s disease, other forms of dementia and Parkinson’s disease. More...

John Hardy, PhD, right, accepted the 2015 Robert A. Pritzker Prize from MJFF VP Brian Fiske, PhD, and Michael J. Fox on April 15.

John Hardy awarded 2015 Robert A. Pritzker Prize for Leadership in Parkinson's Research

One of the UK Parkinson's Disease Consortium Principal Investigators, Prof John Hardy, has been awarded the 2015 Robert A. Pritzker Prize for his leadership in Parkinson's genetics research. The award was presented by Michael J. Fox at a ceremony in New York on April 15. From the Michael J. Fox Foundation website: More...

Webcast - Prof Nicholas Wood - Advances in Genetic Understanding of Parkinson's Disease.

Video: Advances in Genetic Understanding of Parkinson's Disease

Webcast of the presentation entitled ‘Advances in Genetic Understanding of Parkinson's Disease’ given by Nicholas Wood (University College London, United Kingdom) presented at the Biochemical Society Hot Topic event, PINK1-Parkin Signalling in Parkinson’s Disease and Beyond, held in December 2014. More...

Pedigrees and I-FP-CIT SPECT scan images of the four families with GCH1 mutations involved in this study.

GCH1 gene and Parkinson's risk

A study published in Brain, led by researchers at UCL Institute of Neurology, has shown that genetic mutations which cause a decrease in dopamine production in the brain and lead to a form of childhood-onset Dystonia, also play a role in the development of Parkinson’s disease.

The new Leonard Wolfson Experimental Neurology Centre (LWENC) has opened for clinical studies and trials

23 May 2014

Leonard Wolfson Experimental Neurology Centre (LWENC)

The new clinical trials unit was established through a £20M capital award from the Wolfson Foundation to support high quality translational research and early intervention studies (both outpatient and inpatient) in Healthy Volunteers and patients.

It operates 24hr/day through the partnership between the UCL Institute of Neurology and the National Hospital for Neurology and Neurosurgery (NHNN), UCLH at Queen Square.

LWENC Clinical Facility has been specifically designed to undertake experimental medicine studies and early phase clinical trials (including first-in-man studies) aiming at identifying potential disease modifying therapies in the field of Neurology and Neurodegeneration. These include Alzheimer's Disease, Parkinson’s disease, Huntington’s disease, Multiple Sclerosis, Stroke and Prion disease.

Location within the NHNN gives the LWENC unrivalled access to patients across age ranges, ethnicity and disease. The unit brings together the expertise of UCLH’s and UCL’s leading clinicians and scientists across a broad range of neurological and neurodegenerative diseases with renowned international collaborators and industry partners - the focus is on experimental medicine and early phase trials in patients and healthy volunteers.

We have exciting years ahead of us. Our mission is to provide world class clinical and governance expertise and infrastructure to expedite translational research and the early evaluation of novel treatments for neurodegenerative diseases. I, along with the rest of the LWENC team, am looking forward to this exciting venture at Queen Square.

Dr Vincenzo Libri, Head of the LWENC Clinical Facility

Strong working relationships are established between the LWENC and key service supports within UCLH and UCL, including the Joint Research Office, Pharmacy, Imaging and the Neuroscience Laboratories for blood and CSF biomarkers. Since it opened, the Centre has adopted more than 20 clinical trials in patients.

Leonard Wolfson Experimental Neurology Centre (LWENC)

The Centre has three inpatient rooms and an infusion suite with three recliner chairs and has been designed to provide close monitoring in a relaxed and comfortable environment.

It also houses a consulting room and a laboratory for processing and storage of research samples. 

The Centre is staffed with an experienced medical and nursing team who are fully trained in research governance and regulatory affairs and can provide administrative support for developing protocols and completing regulatory documents and contracts. All members of staff are GCP trained and hold different levels of training in medical emergencies, including Advanced Life Support (ALS) as standard for doctors and Immediate Life Support (ILS) as standard for nurses.

Immediate access ensures that patient safety is at the core of running successful clinical trials with safe drug administration and highly efficient monitoring and management of emerging clinical abnormalities and/or adverse reactions.

Edwina Saunders, Senior Research Nurse

The LWENC is located on the Ground Floor of the Albany Wing at the NHNN, giving immediate access to ICU and a 24-hour emergency response team who can arrive at the Centre within two minutes of an emergency. This, coupled with the experienced and fully trained in-house clinical team, ensures the successful set up of safe drug administration, advanced sampling and highly efficient monitoring/management of emerging clinical abnormalities and/or adverse reactions to study drugs.

Contact details for queries:

  • Manoj Maistry-Administrator: 0203448431
  • Marivic Ricamara-Acting Lead Nurse: 07957479199
  • Edwina Saunders-Senior Research Nurse: 07956727692

Further information

Wolfson foundation

LWENC website

UCL press release on LWENC launch

Page last modified on 23 may 14 10:36